Zakir Siddiquee

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index785citations27works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA Research and Splicing(5), Sarcoma Diagnosis and Treatment(4), RNA modifications and cancer(4), Cancer Research and Treatments(4), Glycosylation and Glycoproteins Research(3)

Publications27 total

Engineered human sialidase as a novel cancer therapeutic targeting immune-suppressive sialoglycans in tumors
2025Open Access
1634 Fetal SARS-CoV-2 Giant Cell Myocarditis in an Expectant Patient with Long COVID
Laboratory Investigation·2025
Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients
npj Vaccines·2023· 68 citedOpen Access
Supplemental figures S1-9 from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
supplemental figure legends from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
supplemental figure legends from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
Data from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
Data from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
Supplemental figures S1-9 from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
843 Development and engineering of human sialidase for degradation of immunosuppressive sialoglycans to treat cancer
Regular and Young Investigator Award Abstracts·2021· 2 citedOpen Access
Abstract LB-109: A novel therapeutic modality of inhibiting the glyco-immune checkpoint axis to treat cancer
Cancer Research·2019· 3 cited
Abstract LB-109: A novel therapeutic modality of inhibiting the glyco-immune checkpoint axis to treat cancer
Experimental and Molecular Therapeutics·2019
Abstract 3827: Preclinical characterization of DCR-BCAT as a component of combination therapy
Cancer Research·2016· 1 cited
Abstract 2925: Anti-tumor activity of a MYC-targeting dicer substrate siRNA in combination with BRD4/CDK7 inhibitors
Cancer Research·2016· 6 cited
Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
Molecular Cancer Therapeutics·2016· 61 citedOpen Access
MAP3K11/GDF15 axis is a critical driver of cancer cachexia
Journal of Cachexia Sarcopenia and Muscle·2015· 174 citedOpen Access
An elevated IgG4 response in chronic infectious aortitis is associated with aortic atherosclerosis
Modern Pathology·2015· 10 cited
Abstract 2990: Notch1 monoclonal antibody inhibits tumor growth and modulates angiogenesis
Cancer Research·2014· 1 cited
Abstract 1441: Induction of cancer cachexia by inflammatory molecules in directed complementation tumor models
Cancer Research·2014
Altered vascular activation due to deficiency of the NADPH oxidase component p22phox
Cardiovascular Pathology·2013· 10 cited
page 1 of 2Next →

Frequent Co-authors

Shanthi Ganesh(9), Dongyu Chen(9), Edmond Chipumuro(9), Marc Abrams(9), Martin L. Koser(8), Wendy A. Cyr(8), Girish R. Chopda(8), Purva Pandya(8), Xue Shui(7), Bo Ying(7), Cheng-Jung Lai(7), Henryk Dudek(7), Satdarshan P. Monga(7), Weimin Wang(7), Bob D. Brown(7), Kevin Craig(6), James R. Stone(5), Junyan Tao(5), Ralph V. Shohet(4), Jenny Che(4)